CD38 and neoplasm: In addition to CDC, the binding of daratumumab to CD38 on the surface of tumor cells has been shown to induce antibody‐dependent cellular cytotoxicity (ADCC), antibody‐dependent cellular phagocytosis (ADCP), tumor cell apoptosis, and modulation of the enzymatic activity CD38 (Fig. 1).